Bryan Norrie is a partner at Aitken Klee LLP in the Ottawa office.
Mr. Norrie specializes in the litigation of pharmaceutical and biotechnology patents. He has a M.Sc. in Neuroscience and Biomedical Engineering, and is a registered Canadian patent agent. Mr. Norrie enjoys combining his technical and legal expertise to identify creative approaches to complex issues. He has been included in the IAM Patent 1000 guide to the world’s leading patent professionals (2015, 2016, 2017), and regularly appears in the Federal Court of Canada and Federal Court of Appeal in trials, application hearings, motions and appeals.
Bar Admission, Ontario – 2007
Registered Patent Agent, Canada – 2009
BCL/LLB 2006 – McGill University – with distinction
MSc 2003 (Neuroscience and Biomedical Engineering) – University of Alberta
BSc 2000 (Physiology, 1st class honours) – University of Alberta
Teva Canada Limited v. Janssen Inc., 2017 FC 434
Teva Canada Limited v. Pfizer Canada Inc., 2017 FC 332
Eli Lilly Canada Inc. v. Teva Canada Limited, 2017 FC 88
Teva Canada Limited v. Pfizer Canada Inc., 2016 FCA 248
Teva Canada Limited v. Janssen Inc., 2016 FC 318
Teva Canada Limited v. Pfizer Canada Inc., 2015 FCA 280
Janssen Inc. v. Teva Canada Limited, 2015 FCA 36
Janssen Inc. v. Teva Canada Limited, 2015 FC 247
Janssen Inc. v. Teva Canada Limited, 2015 FC 184
Teva Canada Limited v. Pfizer Canada Inc., 2014 FC 248
Teva Canada Limited v. Wyeth LLC, 2012 FCA 141
T-1399-15 – Teva v. Pfizer (Desvenlafaxine NOC)
T-894-13 – Teva. v Mylan (Copaxone NOC)
T-989-12 – Amgen v Teva (recombinant G-CSF NOC)
IAM Patent 1000 – ranked as one of the world’s leading patent practitioners (2015, 2016, 2017)
Patent Litigation, Intellectual Property Litigation: Forms and Precedents (Paul Lomic, ed., 2016, LexisNexis Canada)
Utility, Intellectual Property Law Benchbook (Donald M. Cameron, ed., 2014, prior editions published 2012, 2010, 2007, Carswell).
Speaker: Intellectual Property Litigation, Ontario Bar Association, November 22, 2016
Reduced functional recovery by delaying motor training after spinal cord injury. Norrie BA, Nevett-Duchcherer JM, Gorassini MA. J Neurophysiol. 2005 Jul;94(1):255-6
In-situ crosslinking thermoreversible polymers for cell entrapment. Norrie B, Jalil A, Lakey JR, Rajotte RV, Uludag H. Adv Exp Med Biol. 2004;553:19-28.
Engineering temperature-sensitive poly(N-isopropylacrylamide) polymers as carriers of therapeutic proteins. Uludag H, Norrie B, Kousinioris N, Gao T. Biotechnol Bioeng. 2001 Jun 20;73(6):510-21.
Intellectual Property Institute of Canada – Patent Legislation Committee
Canadian Bar Association